AIN and Anal Cancer - ESCP

Salvage immunotherapy may be superior to abdominoperineal resection in node-positive anal squamous cell carcinoma with residual disease after chemoradiation

info@escp.eu.com (ESCP Secretariat) — Mon, 24 Nov 2025 13:56:46 +0000

Free paper - Marianna Sarkissyan at ESCP Paris 2025

What trainees need to know to about AIN

info@escp.eu.com (ESCP Secretariat) — Fri, 21 Nov 2025 15:56:35 +0000

Trainee video session - Micol Lupi at ESCP Paris 2025

Local excision with selective use of reduced dose postoperative chemoradiotherapy in early stage anal cancer: short term results of the phase II PLATO-ACT3 non-randomised trial ISRCTN88455282

info@escp.eu.com (ESCP Secretariat) — Fri, 21 Nov 2025 11:13:26 +0000

One of the Six Best PFP papers - Andrew G Renehan at ESCP Paris 2025

Artificial intelligence and anal cancer screening: first multicentric application of a trinary model for anal lesion detection and classification in high-resolution anoscopy

info@escp.eu.com (ESCP Secretariat) — Fri, 21 Nov 2025 11:08:14 +0000

One of the Six Best PFP papers - Miguel Martins at ESCP Paris 2025

Anal melanoma

info@escp.eu.com (ESCP Secretariat) — Wed, 22 Nov 2023 18:10:48 +0000

Consultants corner - Raminta Luksaite Lukste (Lithuania) at ESCP Vilnius 2023

Core subject update: AIN/Anal cancer

info@escp.eu.com (ESCP Secretariat) — Tue, 21 Nov 2023 07:53:02 +0000

Education session - Sarah MIlls (United Kingdom) at ESCP Vilnius 2023

Atypical colitis, proctology and anal neoplasia: Condylomata, HPV, and AIN

info@escp.eu.com (ESCP Secretariat) — Mon, 04 Nov 2019 00:18:00 +0000

Symposium - Andreas Salat (Austria) at ESCP Vienna 2019

Atypical colitis, proctology and anal neoplasia: Personalised anal cancer management in 2020

info@escp.eu.com (ESCP Secretariat) — Mon, 04 Nov 2019 00:18:00 +0000

Symposium - Marianne G. Guren (Norway) at ESCP Vienna 2019

Trainee Video Session: High resolution anuscopy (HRA)

info@escp.eu.com (ESCP Secretariat) — Mon, 04 Nov 2019 00:14:00 +0000

Educational session - Carlo Ratto (Italy) at ESCP Vienna 2019

In vivo and in vitro efficacy of dual PI3K/mTOR inhibition in novel murine models of anal cancer

info@escp.eu.com (ESCP Secretariat) — Mon, 13 Nov 2017 11:28:00 +0000

ASCRS Visiting Fellow Free Paper - Brooks Rademacher at ESCP Berlin 2017

Anal Intraepithelial Neoplasia and Anal Cancer (Chapter 27, European Manual of Medicine: Coloproctology Second Edition)

sandra.lesny@springer.com (European Manual of Medicine: Coloproctology) — Thu, 18 May 2017 00:00:00 +0100

Within the past few decades the incidence of anal cancer has increased worldwide, especially among the male homosexual population (men who have sex with men [MSM]), with an incidence up to 225 in 100,000. Human papillomavirus (HPV) infections are a main risk factor for the occurrence of anal cancer. The prevalence of anal HPV infection in human immunodeficiency virus (HIV)–negative MSM is 50–60 %, whereas the prevalence reaches almost 100 % in HIV-positive MSM. Anal intraepithelial neoplasia (AIN), which is associated with HPV, has been identified as a precursor lesion for anal cancer. Approximately 20 % of HIV-negative MSM are diagnosed with AIN, and high-grade epithelial neoplasia is already present in 5–10 %. The prevalence of high-grade AIN among HIV-positive MSM is considerably higher and can reach 50 %. In hypothetical models, screening examinations such as anal cytology and high-resolution anoscopy have been shown to be cost-effective and efficient in MSM. Based on these findings, regular anal screening tests should be recommended for at-risk patients. If anal cancer is diagnosed, positron emission tomography/computed tomography is recommended for staging. Radiochemotherapy is the standard treatment for most patients. Surgery is only advisable in patients with small tumors (<2 cm) of the anal margin or as a salvage procedure. Follow-up should be performed for 3 years and should include digital rectal examination and palpation of inguinal lymph nodes.

Core Subject Update: AIN

info@escp.eu.com (ESCP Secretariat) — Thu, 03 Nov 2016 09:46:28 +0000

Educational session - Daniel Dindo at ESCP Milan 2016

AIN and anal malignancy: AIN

info@escp.eu.com (ESCP Secretariat) — Wed, 25 Nov 2015 04:05:16 +0000

Symposium - Daniel Dindo at ESCP Dublin 2015

AIN and anal malignancy: Pathological spectrum of anal neoplasia

info@escp.eu.com (ESCP Secretariat) — Wed, 25 Nov 2015 04:05:16 +0000

Symposium - Marianna Berho at ESCP Dublin 2015

AIN and anal malignancy: Salvage surgery for anal cancer

info@escp.eu.com (ESCP Secretariat) — Wed, 25 Nov 2015 04:05:16 +0000

Symposium - Evgeny Rybakov at ESCP Dublin 2015

Salvage surgery for anal squamous cell carcinoma: prognostic factors for recurrence and survival

info@escp.eu.com (ESCP Secretariat) — Fri, 12 Dec 2014 14:00:55 +0000

Oral Poster (Neoplasia) - Maziar Nikberg at ESCP Barcelona 2014

Identification and exploration of novel therapeutic targets for anal cancer

info@escp.eu.com (ESCP Secretariat) — Thu, 07 Aug 2014 00:00:00 +0100

CSSANZ Travelling Fellow visiting paper - Maria-Pia Bernardi (Australia) at Tripartite Colorectal Meeting 2014

Laser therapy for HPV perineal lesions

info@escp.eu.com (ESCP Secretariat) — Thu, 07 Aug 2014 00:00:00 +0100

Video Presentation - Guillermo Rosato (Argentina) at Tripartite Colorectal Meeting 2014

Patterns of treatment failure for anal squamous cell cancer: thirty years experience in a single institution

info@escp.eu.com (ESCP Secretariat) — Wed, 06 Aug 2014 19:00:00 +0100

Short Paper - Maria-Pia Bernardi (Australia) at Tripartite Colorectal Meeting 2014

Prognostic factors for survival in squamous cell anal carcinoma

info@escp.eu.com (ESCP Secretariat) — Wed, 06 Aug 2014 19:00:00 +0100

Short Paper - Zainul Abedin Kapacee (UK) at Tripartite Colorectal Meeting 2014